Skip to main content

Table 3 Changes in the prevalence of the use of specific psychotropic drug groups among adults aged 60-79 years in Germany. National Health Interview and Examination Surveys GNHIES98 (1997–99) and DEGS1 (2008–11)

From: Changes in prevalence of psychotropic drug use and alcohol consumption among the elderly in Germany: results of two National Health Interview and Examination Surveys 1997-99 and 2008-11

  GNHIES98a DEGS1a Change in % (GNHIES98-DEGS1)
  n % 95% CI n % 95% CI Unadjusteda 95% CI p value Adjusteda,b 95% CI p value
1. All anti-depressants (St. John’s wort and all synthetical antidepressants) 96 6.4 5.2 7.9 173 7.9 6.5 9.5 1.4 -0.6 3.4 .157 1.7 -1.8 5.2 0.343
 1.1 St. John’s wort (N06AP) 47 2.9 2.1 3.9 27 1.1 0.8 1.7 -1.7 -2.7 -0.8 <.001 -5.0 -7.9 -2.0 0.001
 1.2 All synthetical antidepressants 54 3.9 2.9 5.2 151 6.9 5.5 8.5 3.0 1.2 4.8 .001 6.0 2.5 9.4 0.001
  1.2.1. NSMRIsc (N06AA) 45 3.6 2.6 4.8 80 3.8 2.8 5.2 0.3 -1.3 1.8 .741 0.4 -2.7 3.5 0.806
  1.2.2. SSRIsd (N06AB) 3 0.3 0.1 1.0 47 2.0 1.4 2.7 1.7 1.0 2.4 .001 4.1 2.4 5.8 <.0001
2. All hypnotics & sedatives (synth., antihistamines and phytoceuticals) 62 3.6 2.8 4.8 98 3.3 2.6 4.3 -0.3 -1.6 1.0 .644 -1.3 -3.5 0.9 0.234
 2.1 All synth. (N05C) and antihistamines (N05CM) 31 1.6 1.1 2.4 52 1.6 1.1 2.2 0.0 -0.9 0.8 .921 -0.1 -1.7 1.4 0.861
  2.1.1. Hypnotics & sedatives (N05C) 31 1.6 1.1 2.4 42 1.3 0.9 1.9 -0.3 -1.1 0.5 .430 -0.6 -2.2 0.9 0.412
 2.2. All phytoceuticals 32 2.1 1.4 3.0 51 1.9 1.3 2.6 -0.2 -1.2 0.8 .703 -0.6 -1.9 0.6 0.307
  2.2.1. Valerian (N05CP) 28 1.8 1.2 2.7 42 1.5 1.0 2.1 -0.3 -1.2 0.6 .453 -0.5 -1.7 0.7 0.408
3. Benzodiazepines and benzodiazepine-related drugs 64 3.9 2.9 5.2 84 3.3 2.4 4.4 -0.6 -2.1 0.8 .389 -2.0 -5.0 0.9 0.176
 3.1. Benzodiazepines (N05BA, N05CD, N03AE01) 57 3.7 2.8 5.0 57 2.5 1.8 3.5 -1.2 -2.6 0.2 .081 -3.4 -6.3 -0.4 0.024
 3.2. Benzodiazepine-related drugs (Z-drugs) (N05CF) 8 0.2 0.1 0.5 28 0.8 0.5 1.3 0.6 0.2 1.0 .003 1.3 0.6 2.1 <0.001
4. All anti-dementia drugs incl. ginkgo biloba 34 2.2 1.4 3.4 97 4.2 3.3 5.4 2.0 0.7 3.3 .005 3.2 1.3 5.1 0.001
 4.1. Ginkgo biloba (N06DP01) 34 2.2 1.4 3.4 88 3.8 2.9 4.8 1.6 0.3 2.8 .022 2.4 1.0 3.8 0.001
5. Narcotic analgesics (N02A) 39 3.0 2.1 4.2 96 4.1 3.2 5.3 1.2 -0.3 2.6 .121 3.9 0.5 7.3 0.026
6. Anti-epileptics (N03) 14 1.0 0.5 1.7 63 2.3 1.7 3.3 1.4 0.4 2.3 .008 3.6 1.7 5.5 <0.001
7. Antiparkinson drugs (N04) 19 1.1 .7 1.8 32 1.2 0.7 2.0 0.1 -0.7 0.9 .806 -0.1 -1.4 1.3 0.934
8. Anxiolytics (N05B) 34 2.4 1.6 3.5 48 2.2 1.5 3.1 -0.2 -1.4 1.0 .751 -1.2 -3.2 0.9 0.268
  1. astandardized to the population of 31.12.2010
  2. b adjusted for sex, age group, region, community size, social status, polypharmacy, living alone, recognized disability
  3. cNon-Selective Monoamine Reuptake Inhibitors
  4. dSelective Serotonin Reuptake Inhibitors
  5. Figures in bold denote statistical significance